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>1.5mm were analyzable by MSCT. Table shows the diagnostic accuracy of
MSCT compared to CA for the detection of significant CAD.
The total amount of iodine agent was higher with MSCT 139±43 ml (64-
row), 91±9 ml (256 row) vs. 56±19 ml (CA) (p<0.05), as the effective dose
20±13 mS (64-row), 17±6 mS (256-row) vs. 6±4 mSv (CA) (p<0.05).
Conclusions: New generations of multidetector MSCT (64–/256-row)
have a good negative predictive value for the systematic rule out of significant
(>50%) coronary vasculopathy in heart transplant patients and can represent
an alternative to CA in patients without significant stenosis. However, safety
concerns (contrast agent, radiation) remain in the setting of annual coronary
assessment.
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The pathogenesis of vasospastic angina remains incompletely elucidated.
Among multiple mechanisms, abnormalities in the autonomic innervation
have been underscored. As vagal withdrawal can act as a trigger for sponta-
neous coronary spasm, changes in sympathetic activity have also been sug-
gested as individual or combined risk factors for vasospastic angina. Previous
study based on heart rate variability analysis showed both a reduction and an
enhancement of sympathetic nervous activity in patients with variant angina,
but direct assessment of sympathetic nerve activity, using Muscle sympathetic
nerve activity (MSNA) has never been performed.
We evaluated MSNA, haemodynamic parameters (Blood Pressure, Heart
Rate etc..) in 22 patients: 11 having definite vasospastic angina confirmed by
ergonovine provocation test during angiography and 11 matched patients (for
age, gender, body mass index, distribution of risk factors, treatment) with a
negative for provocation test. Parameters were collected during baseline and
during a mental stress known to further increase MSNA. 
At baseline, there were no significant difference between patients with and
without spasm for MSNA (56.9±1.78 burst/min vs. 52.0±2.78 burst/min; n.s.)
and haemodynamic parameters. During mental stress period, patients with
vasospastic angina presented a higher sympathetic nerve activity in compar-
ison to control patients (66.45 burst/min vs. 59.45 burst/min; p<0.05) without
significant difference on heamodynamic parameters.
Our results show for the first time a direct evidence of increased sympa-
thetic activity in patients with vasospastic angina, during mental stress. This
propensity to further increase MSNA during stress may play a key role in the
pathogenesis and occurrence of coronary spasm.
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Purpose: Primary PCI of STEMI is a highly thrombotic situation where
fast and potent platelet inhibition is preferred. No single trial has ever shown
a long-term cardiovascular mortality benefit with a P2Y12 receptor antagonist
in this situation.
Methods. We performed a meta-analysis of randomized trials that com-
pared new P2Y12 receptor antagonists with clopidogrel in Primary PCI of
STEMI on mortality, ischemic outcomes and bleeding events. Data at longest
available follow-up from 4 studies were analysed (TRITON STEMI primary
PCI, CHAMPION PCI, PLATO STEMI and ERASE MI). 
Results: 11934 patients were included; 5925 received new P2Y12 inhibi-
tors (1203 prasugrel, 487 cangrelor, 4201 ticagrelor, and 34 elinogrel) and
6009 received clopidogrel (loading dose ranging from 300 to 600mg). Median
time from admission to PCI was 5 hours. 58.50% of patients received UFH,
30.33% LMWH, and 8.91% bivalirudin or fondaparinux. 46.66% were treated
by additional antiGpIIbIIIa. All patients received aspirin. New P2Y12 inhibi-
tors significantly reduced MACE from 10.85% to 9.32% (p=0.006), any death
from 5.43% to 4.3% (p=0.004), CV death from 4.96% to 4.03% (p=0.02), and
stent thrombosis from 3.21% to 2.17% (p<0.001). Strokes were increased
from 1.11% to 1.59% (p=0.02). TIMI major (from 7.51% to 7.50%, p=0.63)
or TIMI major+minor bleeding (from 4.96% to 5.98%, p=1) were not different
between the two groups (Figure 1).
Conclusion: In comparison with clopidogrel, new P2Y12 inhibitors signifi-
cantly reduce mortality in primary PCI of STEMI with no increase in bleeding.
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Background: Management of ST elevation myocardial infarction (STEMI)
is mainly based on reperfusion therapy either by thrombolysis or primary
angioplasty (PAMI). However, many patients (pts) do not receive this therapy
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Patient-based 84 10 45 8 37 62.5 93.4 50.0 95.9
Vessel-based 252 12 85 8 63 62.5 97.1 41.5 98.8
Segment-based 1131 13 139 10 109 60.0 99.4 46.2 99.6
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